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1. Introduction 
With the increasing popularity of  social media, consumers now turn to different online 
discussion forums, consumer review sites, weblogs, social network sites and so on to seek 
product information and share their own experiences (Cheung and Thadani, 2010; Davies, 
2008). Consequently, companies today face an increasingly difficult challenge: how to 
communicate with consumers online in a way that encourages trust and engagement? What 
may make things even more complicated is that many companies are now operating in a 
highly regulated environment, with the healthcare industry a typical example of this (Choi 
and Lee, 2007; Huh and Langteau, 2007; Nielson, 2008; von Knoop et al., 2003). Thus, 
pharmaceutical marketers and brand managers must understand how to communicate 
effectively in a highly regulated online environment. 
This short report aims to help such companies to build a sustainable and trustworthy 
relationship with their customers online. To do so, the report considers the subject from the 
perspective of a pharmaceutical company. It will first discuss the current regulations around 
the healthcare industry, highlighting the constraints pharmaceutical marketers need to face. 
Then, it will review current literature discussing healthcare consumers’ online behaviour. In 
particular, it will focus on consumers’ negative comments and their possible impact on the 
business. Finally, the report concludes with some suggestions about how to cope with 
negative comments online and build a reliable relationship with customers. 
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2. Current Regulations around the Healthcare Industry 
Medical Advertising has generated great controversy about whether it can benefit 
consumers and public health (Choi and Lee, 2007; Hoek, 2008). Consequently, 
governments around the world set tight regulations to control pharmaceutical marketing. For 
example, in the United Kingdom, advertising of medicines is controlled by both the 
Medicines and Healthcare products Regulatory Agency (MHRA) and by self-regulation 
administered by trade associations. In particular, based on the Medicines (Advertising) 
Regulations 1994 and the Medicines (Monitoring of Advertising) Regulations 1994, the 
current regulations prohibit advertising for any medicines on prescriptions only. But direct-to-
consumer (DTC) advertising is allowed for non-prescription medicines  
(http://www.mhra.gov.uk/Howweregulate/Medicines/Advertisingofmedicines/index.htm). 
Furthermore, current regulations require all DTC advertising to be factual and balanced. In 
other words, claims in the advertising should be based on scientific research and any 
misleading information is prohibited. This includes the requirement that advertising should 
not give consumers the impression that taking the medical product can enhance health and 
not taking the medical product can affect health. It also prohibits any advertising indicating 
that the effects of taking the medical product are guaranteed and/or that the medical product 
has no side effects  
(http://www.legislation.gov.uk/uksi/1994/1932/regulation/9/made). 
In addition, current regulations require pharmaceutical companies to compile and collate all 
information relating to their products and submit it to relevant government bodies  
(http://www.legislation.gov.uk/uksi/1994/1932/regulation/4/made). 
This, therefore, implies that pharmaceutical marketers have the legal obligation to report any 
negative claims/comments towards their products, albeit true or false.   
In terms of the online environment, the same rules apply. For example, MHRA (2011) 
prohibits consumer websites offering medicinal treatment services to advertise medicines on 
prescriptions only. It also requires these websites to provide balanced information with side 
effects clearly visible to the public. In order to effectively engage consumers in such a highly 
regulated environment, it is imperative to understand their online behaviour. The following 
section discusses this in more detail.  
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3. Online Consumer Behaviour 
Although the published studies on consumers’ responses to online DTC pharmaceutical 
advertising are quite rare, in general they have found that consumers have a positive attitude 
towards it (Alperstein and Peyrot 1993; Choi and Lee, 2007). Such enhanced attitudes are 
very important as more and more consumers are now looking for health or medical 
information online. For example, in the United States, 80% of Americans regularly search 
health information online (Anderson 2004; Drummy, 2002). Actually, a recent survey 
suggests that searching health information has become the third most popular activity online, 
just behind email and product information searches (Fox and Fallows, 2003). This is 
particular evident among those who have chronic medical conditions with 80% of them 
seeking information about their diseases and treatment options via the Internet (Von Knoop 
et al., 2003).  In addition, more than half of consumers gather drug information online before 
they talk to their physicians (Thomaselli and Elkin, 2003) and 80% of them indicate that 
online information influences their interaction with the physician(Choi and Lee, 2007). This is 
probably because consumers view information online as reliable (Wray, 2004), and thus they 
will inquire and/or request the advertised medications from the physician (Bell, Kracitz, and 
Wilkes, 1999; Mehta and Purvis, 2003; Williams and Hensel, 1995).  Physicians’ views 
further confirm this. According to Huh and Langteau (2007), physicians believed that the 
strongest influence of DTC on their patients is in inducing them to ask or request the 
advertised drugs. Ironically, this was also their main concern (Hollon, 1999; Wilkes, Bell, and 
Kravitz, 2000) as they may need to correct patients’ misconceptions (Huh and Langteau, 
2007).   
However, in addition to DTC advertising, consumers are also exposed to health or medical 
related information in other online sources such as blogs and forums. Information in those 
blogs and forums is usually generated by other consumers with the intention of sharing their 
personal experiences of using certain drugs or to seek advice about treatment options for 
certain diseases (Von Knoop et al., 2003). Thus, blogs/forums mainly influence consumers 
via electronic world-of-mouth (WOM). What may worry pharmaceutical marketers is that 
some of the information spread via social media may be negative which can have a 
detrimental impact on their businesses (de Matos and Rossi, 2008; Herr, Kardes, and Kim, 
1991; Richins, 1983). This is because dissatisfied consumers would tell an average of nine 
others about their negative experiences (Blodgett, Granbois and Walter, 1993; Huang et al., 
2011), and thus negative WOM is more influential than positive WOM (Chen, Wang and Xie, 
2011). Hennig-Thurau et al. (2004) further argue that spreading negative WOM is motived by 
consumers’ desire for social interaction, desire for economic incentives, their concern for 
other consumers and the potential to enhance their own self-worth. In other words, negative 
WOM is usually diffused by highly motived consumers. Thus, how to cope with negative 
electronic WOM becomes a critical issue for different pharmaceutical firms. The following 
section discusses this further. 
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4. Coping with Negative electronic WOM 
According to Davies (2008), there are three steps that pharmaceutical marketers can use to 
cope with negative electronic WOM and build trust in a highly regulated online environment. 
4.1. Listen to the conversation 
If brand managers want to address the negative electronic WOM online, the first step is to 
find out what consumers’ complaints or misconceptions are about. Thus, Davies (2008) 
suggests that marketers can go to different online forums and weblogs to read consumers’ 
discussion. In particular, Davies (2008) argues that marketers do no need to worry about 
violation of consumers’ privacy as members of different forums/discussion boards 
understand that any information shared is publicly accessible.  
Alternatively, pharmaceutical marketers can read different reviews about their products, 
especially those written by consumers. Brand managers can also watch different videos 
created by consumers or check input in Wikipedia to understand consumers’ views about 
their products. 
4.2. Facilitate the conversation 
After collating information online, the next step is to build a community to interact with 
consumers directly. For example, GlaxoSmithKline has created a website - www.alli.com.uk 
- for its weight loss product. This website provides consumers with relevant product 
information and gives guidance on how to use the product. It also incorporates a moderated 
discussion forum where registered users can share information with each other. Davies 
(2008) argues that such moderated discussion forums can help brand managers to facilitate 
the conversation among consumers whilst ensuring that consumers discussion does not 
veer off in an inappropriate direction.   
In addition to creating a brand community, brand managers can also provide materials to 
consumers to help them understand their condition and its treatment. Or, brand managers 
can incorporate personal stories of actual consumers on their websites. Both methods can 
avoid unnecessary misconceptions and build trust.  
4.3. Join the conversation 
According to Davies (2008), in order to lead consumer conversations, pharmaceutical 
marketers may consider starting their own blogs. For example, Johnson & Johnson 
(www.jnjbtw.com) has launched its own blog to actively engage with consumers. 
Alternatively, brand managers may consider involvement in online discussion as an 
identified representative of the brand. These strategies can help pharmaceutical marketers 
to clarify consumer misconceptions while diffusing new product information. 
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